Enfuvirtide: The first HIV fusion inhibitor

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 3, 2005, Pages 453-464

  Lazzarin, Adriano ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Enfuvirtide; HIV; HIV fusion inhibitors; T 20

Indexed keywords

AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ENFUVIRTIDE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; LIPID; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CHILL; CLINICAL TRIAL; CROSS RESISTANCE; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECCHYMOSIS; ERYTHEMA; FATIGUE; FEVER; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOTENSION; INJECTION PAIN; INJECTION SITE REACTION; LIVER TOXICITY; MEMBRANE FUSION; MULTIDRUG RESISTANCE; NAUSEA; PATIENT COMPLIANCE; PNEUMONIA; PRURITUS; RASH; REVIEW; RIGOR; SKIN CYST; SKIN INDURATION; SKIN NODULE; TREATMENT FAILURE; VIRUS RESISTANCE; VOMITING;

AMINO ACID SEQUENCE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS;

EID: 17144420144     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.3.453     Document Type: Review

References (81)

1. D'ARMINIO MONFORTE A, LEPRI AC, REZZA G et al.: Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS (2000) 14(5):499-507.
2. LUCAS GM, CHAISSON RE, MOORE RD: Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann. Intern. Med. (1999) 131 (2):81-87.
3. SHAFER RW, WINTERS MA, PALMER S, MERIGAN TC: Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann. Intern. Med. (1998) 128(11):906-911.
4. MAEDA K, NAKATA H, OGATA H et al.: The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection. Curr. Opin. Pharmacol. (2004) 4 5):447-452.
5. GREENBERG M, CAMMACK N, SALGO M, SMILEY L: HIV fusion and its inhibition in antiretroviral therapy. Rev. Med. Virol. (2004) 14 5):321-337.
6. WITVROUW M, VAN MAELE B, VERCAMMEN J. et al.: Novel inhibitors of HIV-1 integration. Curr. Drug Metab. (2004) 5 4):291-304.
7. SEIBERT C, SAKMAR TP: Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs. Curr. Pharm. Des (2004) 10(17):2041-2062.
8. CHAN DC, KIM PS: HIV entry and its inhibition. Cell (1998) 93(5):681-684.
9. WEISSENHORN W, DESSEN A, CALDER LJ et al.: Structural basis for membrane fusion by enveloped viruses. Mol. Membr. Biol. (1999) 16(1):3-9.
10. LALEZARI JP, HENRY K, O'HEARN M et al.: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. Med. (2003) 348(22):2175-2185.
11. LAZZARIN A, CLOTET B, COOPER DA et al.: Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. (2003) 348(22):2186-2195.
12. MATTHEWS T, SALGO M, GREENBERG M et al.: Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat. Rev. Drug Discov. (2004) 3(3):215-225.
13. WILD CT, SHUGARS DC, GREENWELL TK, MCDANAL CB, MATTHEWS TJ: Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus Type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. USA (1994) 91 21):9770-9774.
14. CHAN DC, CHUTKOWSKI CT, KIM PS: Evidence that a prominent cavity in the coiled coil of HIV Type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. USA (1998) 95(26):15613-15617.
15. KLIGER Y, SHAI Y: Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation. J. Mol. Biol. (2000) 295 2):163-168.
16. JONES PL, KORTE T, BLUMENTHAL R: Conformational changes in cell surface HIV-1 envelope glycoproteins are triggered by cooperation between cell surface CD4 and co-receptors. J. Biol. Chem. (1998) 273(1):404-409.
17. MUNOZ-BARROSO I, DURELL S, SAKAGUCHI K, APPELLA E, BLUMENTHAL R: Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J. Cell Biol. (1998) 140(2):315-323.
18. KLIGER Y, GALLO SA, PEISAJOVICH SG et al.: Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage. J. Biol. Chem. (2001) 276(2):1391-1397.
19. LAWLESS MK, BARNEY S, GUTHRIE KI et al.: HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41. Biochemistry (1996) 35 42):13697-13708.
20. NAGASHIMA KA, THOMPSON DA, ROSENFIELD SI et al.: Human immunodeficiency virus Type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J. Infect. Dis. (2001) 183(7):1121-1125.
21. PINE PS, WEAVER JL, ORAVECZ T et al.: A semiautomated fluorescence-based cell-to-cell fusion assay for gp120-gp41 and CD4 expressing cells. Exp. Cell Res. (1998) 240(1):49-57.
22. GREENBERG ML, MELBY T, SISTA P, et al.: Baseline and on-treatment susceptibility to enfuvirtide seen in TORO 1 and TORO 2 to 24 weks. 10th Conference on Retroviruses and Opportunistic Infections Boston, MA, USA February (2003) Abstract 141.
23. DERDEYN CA, DECKER JM, SFAKIANOS JN et al.: Sensitivity of human immunodeficiency virus Type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. (2000) 74(18):8358-8367.
24. DERDEYN CA, DECKER JM, SFAKIANOS JN et al.: Sensitivity of human immunodeficiency virus Type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J. Virol. (2001) 75(18):8605-8614.
25. LABROSSE B, LABERNARDIERE JL, DAM E et al.: Baseline susceptibility of primary human immunodeficiency virus Type 1 to entry inhibitors. J. Virol. (2003) 77(2):1610-1613.
26. WHITCOMB JM, HUANG W, FRANSEN S, et al.: Analysis of baseline enfuvirtide (T20) susceptibility and co-receptor tropism in two Phase III study populations. 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA (2003) Abstract.
27. SISTA P, MELBY T, DHINGRA U, et al.: The fusion inhibitors T-20 and T-1249 demonstrate potent in vitro antiviral activity against clade-B HIV-1 isolates resistance to reverse transcriptase and protease inhibitors and non-B clades. Antivir. Ther. (2001) 6(Suppl. 1):3-4.
28. CILLIERS T, PATIENCE T, PAPATHANASOPOLOUS MA, MORRIS L: Sensitivity of HIV-1 subtype C isolates to the fusion inhibitor T-20. Antivir. Ther. (2003) 8(Suppl. 1):S210.
29. POVEDA E, RODES B, TORO C, SORIANO V: Are fusion inhibitors active against all HIV variants? AIDS Res. Hum. Retroviruses (2004) 20(3):347-348.
30. COOPER DA, LANGE JM: Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development. Lancet Infect Dis. (2004) 4(7):426-436.
31. GREENBERG ML, CAMMACK N: Resistance to enfuvirtide, the first HIV fusion inhibitor. J. Antimicrob. Chemother. (2004) 54 2):333-340.
32. ZOLLNER B, FEUCHT HH, SCHROTER M et al.: Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patients. AIDS (2001) 15(7):935-936.
33. RIMSKY LT, SHUGARS DC, MATTHEWS TJ: Determinants of human immunodeficiency virus Type 1 resistance to gp41-derived inhibitory peptides. J. Virol. (1998) 72(2):986-993.
34. WEI X, DECKER JM, LIU H et al.: Emergence of resistant human immunodeficiency virus Type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. (2002) 46(6):1896-1905.
35. MINK M, GREENBERG ML, MOSIER S et al.: Impact of HIV-1 gp41 amino acid substitutions (positions 36-45) on susceptibility to T-20 (enfuvirtide) in vitro: analysis of primary virus isolates receovered from patients during chronic enfuvirtide treatment and site directed mutants in NL4-3. Antivir. Ther. (2002) 7(Suppl. 1):S24.
36. JOHNSON VA, BRUN-VEZINET F, CLOTET B et al.: Drug resistance mutations in HIV-1. Top HIV Med. (2003) 11 (6):215-221.
37. LU J, SISTA P, GIGUEL F, GREENBERG M, KURITZKES DR: Relative replicative fitness of human immunodeficiency virus Type 1 mutants resistant to enfuvirtide (T-20). J. Virol. (2004) 78 9):4628-4637.
38. BALDWIN CE, SANDERS RW, DENG Y et al.: Emergence of a drug-dependent human immunodeficiency virus Type 1 variant during therapy with the T20 fusion inhibitor. J. Virol. (2004) 78 22):12428-12437.
39. KILBY JM, HOPKINS S, VENETTA TM et al.: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. (1998) 4 11):1302-1307.
40. KILBY JM, LALEZARI JP, ERON JJ et al.: The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res. Hum. Retroviruses (2002) 18 10):685-693.
41. WHEELER DA, LALEZARI JP, KILBY JM et al.: Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected parients. J. Clin. Virol. (2004) 30(2):183-190.
42. ZHANG X, NIEFORTH K, LANG JM et al.: Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition. Clin. Pharmacol. Ther. (2002) 72 1):10-19.
43. ZHANG X, BUSS N, SALGO M, PATEL IH: Enfuvirtide pharmacokinetic-pharmacodynamic (PK-PD) relationship. 9th European AIDS Conference. Warsaw, Poland (2003). Abstract 4.1/4.
44. THOMPSON M, TRUE A, CHIU YY et al. Pharmacokinetic (PK), pharmacodynamic, and safety assessment of qd versus bid dosing with enfuvirtide in HIV infected subjects. 44th Interscience Conference on Antimicrob. Agents Chemother Washington DC, USA, October 30 - November 2 (2004). Poster H-866.
45. LALEZARI JP, PATEL IH, ZHANG X et al.: Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients. J. Clin. Virol. (2003) 28(2):217-222.
46. Roche Pharmaceuticals: FUZEON© US Product Information, Roche Pharmaceuticals (2003).
47. LEEN C, WAT C, NIEFORTH K: Pharmacokinetics of enfuvirtide in a patient with impaired renal function. Clin. Infect. Dis. (2004) 39(11):e119-e121.
48. BELLIBAS SE, SIDDIQUE Z, DORR A, et al.: Pharmacokinetics of enfuvirtide in pediatric HIV infected patients receiving combination therapy. Antivir. Ther. (2003) 8(Suppl. 1):S421.
49. MEYOHAS MC, LACOMBE K, CARBONNE B, MORAND-JOUBERT L, GIRARD PM: Enfuvirtide prescription at the end of pregnancy to a multi-treated HIV-infected woman with virological breakthrough. AIDS (2004) 18 14):1966-1968.
50. ZHANG X, LALEZARI JP, BADLEY AD et al.: Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus Type 1-infected patients. Clin. Pharm. Ther. (2004) 75 6):558-568.
51. BOYD MA, ZHANG X, DORR A et al.: Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide. J. Clin. Pharmacol. (2003) 43(12):1382-1391.
52. RUXRUNGTHAM K, BOYD M, BELLIBAS SE et al.: Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1 infected patients. J. Clin. Pharmacol. (2004) 44(7):793-803.
53. LALEZARI JP, ERON JJ, CARLSON M et al.: A Phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS (2003) 17 5):691-698.
54. PIKETTY C, RACE E, CASTIEL P et al.: Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS (1999) 13(11):F71-F77.
55. LALEZARI JP, DEJESUS E, NORTHFELT DW et al.: A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir. Ther. (2003) 8(4):279-287.
56. CHURCH JA, HUGHES M, CHEN J et al.: Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. Pediatr. Infect. Dis. J. (2004) 23 8):713-718.
57. CHURCH JA, CUNNINGHAM C, HUGHES M et al.: Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. Pediatr. Infect. Dis. J. (2002) 21(7):653-659.
58. WIZNIA A, CHURCH J, STAVOLA J, et al.: 24-week safety and efficacy of enfuvirtide as part of an optimized regimen in adolescents. 11th Conference on Retroviruses and Opportunistic Infections. San Fransisco, CA, USA (2004). Abstract 929.
59. KATLAMA C, ARASTÉH K, CLOTET B et al.: Enfuvirtide TORO studies: 48 week results confirm 24 week findings. 2nd International AIDS Society Meeting. Paris, France (2003). Abstract LB2.
60. TROTTIER B, ARASTEH K, HENRY K, et al.: Durability of response to enfuvirtide through 48 weeks in the TORO trials. 43rd Interscience Conference on Antimicrob. Agents Chemother. Chicago, IL, USA (2003). Abstract H-835.
61. ARASTEH K, LAZZARIN A, CLOTET B et al.: TORO: 96 week virological and immunological response and safety evaluation of enfuvirtide with an optimized background regimen. XV International AIDS Conference. Bangkok, Thailand (2004). Abstract MoOrB1058.
62. BARTLETT JA, SALGO M, DEMASI R: Early viral load responses on enfuvirtide in heavily treatment-experienced patients. XV International AIDS Conference. Bangkok, Thailand (2004). Abstract TuPeB4484.
63. CLUMECK N, COHEN CJ, THOMPSON M et al.: Impact of enfuvirtide on health-related quality of life at 48 weeks. 9th European AIDS Conference. Warsaw, Poland (2003). Abstract 7.3/19.
64. COHEN CJ, CLUMECK N, MOLINA J-M, et al.: Impact of enfuvirtide on helath-related quality of life. Antivir. Ther. (2003) 8(Suppl. 1):S510.
65. WALMSLEY S, CLOTET B, COOPER D et al.: Efficacy of enfuvirtide in subgroups of patients through 48 weeks of therapy in the TORO trials. 9th European AIDS Conference. Warsaw, Poland (2003). Abstract 7.3/15.
66. MONTANER J: Analysis of virological response to enfuvirtide in TORO: implications for patient management. 2nd International AIDS Society Conference in HIV Pathogenesis and Treatment. (2003). Abstract 116.
67. MONTANER J, CHUNG J, GUIMARAES D et al.: A treatment staging proposal derived from a post-hoc analysis of the 48 week results from the TORO studies. XV International AIDS Conference. Bangkok, Thailand (2004). Abstract TuPeB4483.
68. ERON JJ, DELFRAISSY JF, KURITZKES D, et al.: Safety of enfuvirtide (ENF) through 48 weeks of therapy in the TORO trials. 43rd Interscience Conference on Antimicrob. Agents Chemother. Chicago, IL, USA (2003). Abstract H-836.
69. BALL RA, KINCHELOW T. Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. J. Am. Acad. Dermatol. (2003) 49 5):826-831.
70. MYERS SA, SELIM A, MCDANIEL M, et al.: A prospective clinical and histological examination of injection sites with the HIV fusion inhibitor enfuvirtide (ENF). 43rd Interscience Conference on Antimicrob. Agents Chemother. Chicago, IL, USA (2003). Abstract H-2015.
71. COOPER DA, REISS P, HENRY K et al.: The effects of enfuvirtide therapy on body composition and serum lipids through 48 weeks in the TORO trials. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA (2004). Abstract 715.
72. WALMSLEY S, HENRY K, KATLAMA C et al.: Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide. J. Infect. Dis. (2003) 188 12):1827-1833.
73. HASSON H, DANISE A, CARINI E et al.: Increase in serum IgE levels during enfuvirtide treatment in multidrug-resistant HIV-1 infected patients. XV International AIDS Conference. Bangkok, Thailand (2004). Abstract.
74. WAT C, PANTALEO G, HERATH C et al.: Incidence of baseline elevated serum IgE levels in the HIV-treatment-experienced population of the TORO studies remains stable during treatment and does not correlate with enfuvirtide (ENF) use. 44th Interscience Conference on Antimicrob. Agents Chemother. Washington DC, USA (2004). Poster H-170.
75. YENI PG, HAMMER SM, HIRSCH MS et al.: Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 292(2):251-265.
76. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and adolescents Panel on Clinical Practices for Treatment of HIV Infection (2004).
77. POZNIAK A, GAZZARD B, ANDERSON J. et al.: British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. (2003) 4(Suppl. 1):1-41.
78. COHEN CJ, DUSEK A, GREEN J. et al.: Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living. AIDS Patient Care STDS (2002) 16(7):327-335.
79. GREEN J, KLEINMAN L, CIESLA G et al.: Subcutaneous injection survey: psychometric evaluation of a treatment satisfaction instrument associated with a novel HIV medication. HIV Clin. Trials (2002) 3(5):387-395.
80. COHEN C, HELLINGER J, JOHNSON M et al.: Patient acceptance of self-injected enfuvirtide at 8 and 24 weeks. HIV Clin. Trials (2003) 4(5):347-357.
81. COHEN C, GREEN J, WINTFELD N, PATEL K: Patient acceptance with self-injection of enfuvirtide (ENF) for HIV over 48 weeks of treatment. 9th European AIDS Conference. Warsaw, Poland (2003). Abstract 7.1/1.